We are live on
!
Find out more
SCM
Sarissa Capital Management Portfolio holdings
AUM
$158M
1-Year Est. Return
103.7%
This Fund
S&P 500
This Quarter
Est. Return
+5.6%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$1B
AUM Growth
+$223M
(+28%)
Cap. Flow
+$183M
Cap. Flow
% of AUM
18.24%
Top 10 Holdings %
Top 10 Hldgs %
99.97%
Holding
12
New
1
Increased
3
Reduced
1
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alkermes
ALKS
|
+$154M |
| 2 |
Neurocrine Biosciences
NBIX
|
+$22.6M |
| 3 |
Innoviva
INVA
|
+$8.3M |
| 4 |
Gilead Sciences
GILD
|
+$5.61M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MRSN
Mersana Therapeutics
MRSN
|
+$6.83M |
| 2 |
PEAR
Pear Therapeutics, Inc. Class A Common Stock
PEAR
|
+$128K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Alkermes
ALKS
$8.22B
| $439M | 43.75% |
14,040,000
+5,075,360
| +57% | +$154M |
|
2
Biogen
BIIB
$30B
| $183M | 18.23% |
643,000
| – | – |
|
3
Ironwood Pharmaceuticals
IRWD
$696M
| $174M | 17.36% |
16,390,000
| – | – |
|
|
4
Innoviva
INVA
$1.55B
| $92.6M | 9.22% |
7,277,000
+663,000
| +10% | +$8.3M |
|
|
5
Gilead Sciences
GILD
$162B
| $70.9M | 7.06% |
920,400
+70,400
| +8% | +$5.61M |
|
|
6
Neurocrine Biosciences
NBIX
$16.8B
| $21.8M | 2.17% |
+231,300
| New | +$22.6M |
|
|
MRSN
7
DELISTED
Mersana Therapeutics
MRSN
| $8.66M | 0.86% |
105,316
-46,684
| -31% | -$6.83M |
|
|
AMRN
8
Amarin Corp
AMRN
$298M
| $5.84M | 0.58% |
245,500
| – | – |
|
9
BioCryst Pharmaceuticals
BCRX
$2.28B
| $5.46M | 0.54% |
775,000
| – | – |
|
10
Vor Biopharma
VOR
$1.15B
| $1.91M | 0.19% |
30,900
| – | – |
|
|
RGLS
11
DELISTED
Regulus Therapeutics
RGLS
| $272K | 0.03% |
185,183
| – | – |
|
|
PEAR
12
DELISTED
Pear Therapeutics, Inc. Class A Common Stock
PEAR
| – | – |
-500,356
| Closed | -$128K |
|
Similar funds
4A
DAM
PCP
CF
HEM
SF
AC
EP
Sarissa Capital Management's Q2 2023 Portfolio in Review
As of Q2 2023, Sarissa Capital Management held 12 positions worth $1B, up 28% from $782M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Sarissa Capital Management deployed $183M of net new capital in Q2 2023, opening 1 new position and adding to 3 existing holdings. Its largest new stake was Neurocrine Biosciences: 231,300 shares worth $21.8M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Mersana Therapeutics, an estimated $6.83M trimmed.
- Sarissa Capital Management's largest Q2 2023 buy was Neurocrine Biosciences: 231,300 shares worth $21.8M.
- Sarissa Capital Management added most to Alkermes in Q2 2023, an estimated $154M increase.
- Sarissa Capital Management's biggest Q2 2023 reduction was Mersana Therapeutics, cutting an estimated $6.83M.
- Sarissa Capital Management fully exited Pear Therapeutics, Inc. Class A Common Stock in Q2 2023, selling an estimated $128K.
- Sarissa Capital Management's ten largest holdings make up 100% of its $1B portfolio in Q2 2023.
- Sarissa Capital Management opened 1 new position and closed 1 in Q2 2023.
- Sarissa Capital Management's portfolio value rose 28% quarter-over-quarter to $1B.
Based on Sarissa Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.